Caligor Rx Receives Majority Investment from Diversis Capital

Caligor_RxCaligor Rx, Inc., a Secaucus, New Jersey-based provider of services for pharmaceutical and biotechnology companies to maximize the value of their clinical supply chain investments, has received a majority investment from Diversis Capital, LLC.

The financial terms of the transaction were not disclosed.

Diversis plans to invest in Caligor to enhance its sales and marketing, logistics capabilities, distribution infrastructure and service offerings. These investments will include a new warehouse in Dartford, UK, slated to open in late 2016.

Started in 1919 as a pharmacy and led by CEO Tammy Bishop, Caligor is today a leader in sourcing and distributing comparator drugs for clinical trials worldwide. Complementing its comparator business, the company provides regulatory expertise and strategic services for setting up Global Access Programs (GAP). These programs supply investigational medicines to individual patients, and groups of patients, who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives.



Join the discussion